2022-11-23 • Updated
This week, the stock of AstraZeneca was one of the most traded instruments in FBS Trader! It was even more popular than the stock of Tesla. There has been news that grabbed the attention of traders this week. It’s also worth mentioning the earnings of a company coming out this Friday. What should you know ahead of it?
EPS = 0.62 (vs. 0.47 in Q3 2020)
Revenue = 9520 (vs. 6578 in Q3 2020)
The release of financial results is expected on November 12, at 13:45 GMT+2.
The destiny of the Anglo-Swedish drug giant has been complicated since the start of the Covid-19 pandemic. You may have heard of the news about the vaccine that causes blood clots. As the cases were linked to AstraZeneca’s vaccine, several countries restricted its use. Luckily for AstraZeneca, the European Medicines Agency (EMA) and the World Health Organization (WHO) both confirmed that the vaccine was safe and effective. The organizations said that the number of blood clots was extremely rare. Another challenging factor for the company this year was linked to the production problems. AstraZeneca cut its vaccine deliveries to the EU by half, reportedly due to problems at its plants and delayed testing of a batch of vaccines.
However, the company managed to stabilize its performance in 2021. Last week, it announced the creation of a new division for vaccines and antibody therapies. Vaccines are seen as not a traditional area for the company, so optimization of its structure certainly helps with business processes. Another positive news is the approval of the drug maker’s antibody cocktail against Covid-19 in Australia. Now, the mixture is awaiting a review by the European Medicines Agency.
The first half of the year was the golden time for the company. The Covid vaccine resulted in an outstanding improvement of AstraZeneca’s financial results making 9% out of +18% of the total revenue growth in the first half of the year.
Apart from the vaccine, AstraZeneca has been working on cancer drugs – Lynparza, Tagrisso, Imfinzi, and diabetes medicine. Their sales have been rapidly growing as well. Higher demand for Tagrisso in the United States amid the broad-based adjuvant therapy for treating lung cancer patients may improve the company’s financial results as well. Other medical treatments are also likely to have contributed to sales growth in the third quarter.
The stock of AstraZeneca has been moving within an uptrend. The breakout of the 9500 level will be crucial, as it will lead to the rise to July's all-time high of 10 088. If stock's price breaks below the support of 9240, it will indicate a bearish scenario with the next potential target of 9000.
Summing up, AstraZeneca has a great potential to post good financial results for the third quarter. Its business structure is accelerating and new facilities are developing. Also, it produces necessary drugs for the treatment of Covid-19 and other severe diseases. The demand for this medicine has been growing last quarter and it may attribute to the strong financial report on Friday. Follow the release on Friday at 13:45 GMT+2!
Coinbase (#COIN) saw its revenue rise to $773 million in Q1 2024, marking a 23% increase from the previous quarter and surpassing analyst expectations.
During his program on CNBC on February 28, Jim Cramer expressed frustration with the impact of earnings reports on market behavior, noting how they often prompt rash decisions by average investors. He criticized the short-term focus and lack of attention to nuance in news coverage of earnings. Cramer cited examples of Home Depot and Lowe's, highlighting how investors reacted hastily to headline news without considering the broader context provided in earnings calls.
As the year winds down and the festive spirit takes hold, the stock market often presents a curious yet anticipated phenomenon known as the Santa Rally. Within this whirlwind of festive trading, let’s look at how two titans of the tech world, Amazon and Apple, might fare during this unique season.
Jerome H. Powell, the Federal Reserve chair, stated that the central bank can afford to be patient in deciding when to cut interest rates, citing easing inflation and stable economic growth. Powell emphasized the Fed's independence from political influences, particularly relevant as the election season nears. The Fed had raised interest rates to 5.3 ...
Hello again my friends, it’s time for another episode of “What to Trade,” this time, for the month of April. As usual, I present to you some of my most anticipated trade ideas for the month of April, according to my technical analysis style. I therefore encourage you to do your due diligence, as always, and manage your risks appropriately.
Bearish scenario: Sell below 1.0820 / 1.0841... Bullish scenario: Buy above 1.0827...
FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.
Your request is accepted.
A manager will call you shortly.
Next callback request for this phone number
will be available in
If you have an urgent issue please contact us via
Live chat
Internal error. Please try again later
Don’t waste your time – keep track of how NFP affects the US dollar and profit!
|
